The Clinical Trials Arena team investigates assets in infectious diseases, metabolic disorders, oncology and ophthalmology.
Currently, there are no approved medications for treating nonmonogenic, nonsyndromic obesity in children under 12. While ...
Even with the lifestyle changes being in both groups, children who were using Liraglutide lost significantly more weight than ...
Liraglutide treatment significantly lowers BMI in obese children aged 6 to <12, but gastrointestinal side effects prompt the ...
Liraglutide results in greater reduction in BMI than placebo plus lifestyle intervention for children with obesity ...
Liraglutide is the first GLP-1 agonist to show benefit in this age group and could provide young patients a much-needed ...
The study concentrates on the FDA-approved injectable medications semaglutide and liraglutide. A study conducted by the ...
In the heavyweight title match between weight loss meds, we have ourselves a victor.In the battle between Novo Nordisk’s ...